Company Overview of Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company’s product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ib clinical trials for the treatment of rheumatoid arthritis; and in pre-IND stage for pigmented villonodular synovitis and multiple cancers in combination with nivolumab. Its product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor 2b and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039/GSK3052230, a fus...
Two Corporate Drive
South San Francisco, CA 94080
Founded in 2001
Key Executives for Five Prime Therapeutics, Inc.
Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $525.0K
Chief Medical Officer and Executive Vice President
Total Annual Compensation: $382.1K
Chief Business Officer, Executive Vice President and Director
Total Annual Compensation: $364.0K
Compensation as of Fiscal Year 2014.
Five Prime Therapeutics, Inc. Key Developments
Five Prime Therapeutics and Partner GlaxoSmithKline Reports Initial Data from Phase 1b Trial of Lung Cancer Treatment
Aug 24 15
Five Prime Therapeutics and partner GlaxoSmithKline reported results from the ongoing Phase 1b trial of FP-1039/GSK3052230 in patients with squamous non small cell lung cancer and mesothelioma. The Phase 1B trial being conducted by GlaxoSmithKline is evaluating the safety and efficacy of FP-1039/GSK3052230 weekly infusion in combination with paclitaxel + carboplatin in previously untreated FGFR1 gene amplified metastatic squamous NSCLC (Arm A). It is also evaluating it in combination with docetaxel in FGFR1 gene amplified metastatic squamous NSCLC that has progressed after at least 1 line of chemotherapy (Arm B) and finally in combination with pemetrexed + cisplatin in patients with untreated and unresectable malignant pleural mesothelioma (Arm C). GlaxoSmithKline continues to enroll patients in the study. Arm A and Arm C have advanced into the expansion phase and dose escalation is ongoing for Arm B. Five Prime licensed development and commercialization rights for FP-1039/GSK3052230 in the U.S., Europe and Canada to GSK, which funds clinical development. Five Prime retains rights outside of these regions as well as an option to co-promote FP-1039/GSK3052230 in the U.S.
Five Prime Therapeutics, Inc. Announces Board Changes
Aug 21 15
On August 20, 2015, the Board of Directors of the Five Prime Therapeutics, Inc. approved a change in title for Julia Hambleton and Aron Knickerbocker, with all such changes becoming effective immediately. The new titles of the two Named Officers are identified in the table below: Julie Hambleton Executive Vice President and Chief Medical Officer, Aron M. Knickerbocker Executive Vice President and Chief Business Officer.
Five Prime Therapeutics, Inc. Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Financial Guidance for the Full Year 2015
Aug 6 15
Five Prime Therapeutics, Inc. reported financial results for the second quarter and six months ended June 30, 2015. Net loss for the second quarter of 2015 was $11.5 million, or $0.45 per basic and diluted share, compared with a net loss of $9.9 million, or $0.46 per basic and diluted share, for the second quarter of 2014. This increase in net loss was primarily related to advancing the FPA008 development program into additional indications and expanding internal immuno-oncology research and preclinical activities. Collaboration and license revenue was $6.3 million against $5.0 million a year ago, primarily due to the $1.5 million upfront license payment from bluebird bio.
For the six months, the company reported net loss of $22.5 million or $0.89 per basic and diluted share against $18.5 million or $0.92 per basic and diluted share a year ago. Collaboration and license revenue was $10.6 million against $8.5 million a year ago.
The company expects full-year 2015 net cash used in operating activities to be between $65 and $70 million and estimates ending 2015 with between $158 and $163 million in cash, cash equivalents and marketable securities.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|